



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Date: 13.08.2021

To,

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,


Sub: Outcome of Board meeting

Ref: Our Company's Letter dated 02.08.2021

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Friday, 13.08.2021 at 4:00 p.m. at the registered office of the company, the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.06.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2021. **(Enclosed)**
3. Appointment of Mr. S. Manoj Kumar Reddy as Additional Director (Executive Category) w.e.f 13.08.2021.
4. Resignation of Mr. T. Narsihma Reddy as Managing Director of the Company w.e.f 13.08.2021.
5. Change in designation of Mr. S. Nagi Reddy from Chairman & Whole time Director to Chairman & Managing Director w.e.f 13.08.2021.
6. Resignation of Mr. P. Venkatram Reddy as Independent Director of the Company w.e.f 13.08.2021.
7. Reconstitution of the Audit Committee, Nomination and Remuneration Committee, and Stakeholder's relationship committee.

S. Nagi Reddy



CIN No.: L24230TG1995PLC020093



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsLtd@gmail.com Website : www.concorddrugs.in

8. Notice of 26th Annual General Meeting of the Members of the Company to be held on Tuesday 28th of September, 2021 at 9:00 a.m. through video conferencing/other audio visual means.

Disclosure as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to appointment or resignations as mentioned above is enclosed hereunder.

The meeting concluded at 5:45 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,
For Concord Drugs Limited



S. N. Reddy

S. Nagi Reddy
Chairman & Managing Director
DIN: 01764665

Encl: as above




CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Disclosure as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to appointment or resignations as mentioned above is enclosed hereunder.

S.No.	Particulars	S. Manoj Kumar Reddy	S. Nagi Reddy
1.	Reason for change viz appointment, resignation	Appointment	Appointment (Change in designation)
2.	Date of appointment/Cessation	13.08.2021	13.08.2021 (Change in designation)
3.	Term of Appointment	3 Years Subject to the approval of Members	Till the expiry of the existing tenure
4.	Brief profile (in case of Appointment)	Aged around 30 years, he is an MBA Graduate having experience of almost 8 years in the field of Pharmaceuticals	Aged about 52 years, at present he is a Chairman and Whole-time Director of the Company. He is a Post Graduate and has a rich experience of 30 Years in Pharma Industry.
5.	Relationship with other directors (in case of Appointment)	Son of Mr. S. Nagi Reddy and Brother of Mr. S. Koni Reddy	Father of Mr. S. Koni Reddy and Mr. S. Manoj Kumar Reddy



To,

Date: 13.08.2021

The Board of Directors,
Concord Drugs Limited,
survey no.249, Brahmanapally Village,
Hayatnagar Mandal,
R.R.District-501511,
Telangana

Dear Sir/Madam,

Sub: Resignation as Director of the Company


Due to my commitments and personal pre-occupations, I am not in a position to continue as a Director of Concord Drugs Limited. Hence, I tender my resignation as Independent Director of the Company with effect from 13.08.2021.

I take this opportunity to thank my colleagues on the Board for their continued support and wish them a great success in all their future endeavors.

Further, I would also like to confirm that there is no other material reason other than the one mentioned above, for my resignation from the Board of the Company.

Thanking you.

Yours truly,



P. Venkatram Reddy
(DIN: 07001606)



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2021

[Rs. in Lakhs]

Particulars	Quarterly ended			Year ended
	30-Jun-21 (UnAudited)	31-Mar-21 (Audited)	30-Jun-20 (UnAudited)	31-Mar-21 (Audited)
I Revenue from Operations				
a. Net sales from Operations	2,021.94	834.63	1,820.32	5,135.70
b. Other Operating Income	2.152	2.15	2.15	9.46
II Other Income				
III Total Revenue (I+II)	2,024.10	836.78	1,822.48	5,145.16
IV Expenses				
a. Cost of Material Consumed	1,566.49	552.78	1,497.57	4,049.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	18.48	42.56	96.72	168.67
c. Employees Benefit Expenses	104.88	92.29	87.00	375.55
d. Finance Costs	95.76	27.49	43.91	142.03
e. Depreciation and Amortisation expense	53.16	33.22	31.73	136.53
f. Other expenses	105.30	74.36	43.20	220.35
Total Expenses	1,944.07	822.70	1,800.12	5,092.28
Profit/ (Loss) before Exceptional item and tax (III-IV)	80.03	14.09	22.35	52.88
V Exceptional Items		23.98		376.32
VI Profit/ (Loss) before tax (V-VI)	80.03	38.07	22.35	429.20
VII Tax Expense:	11.26	4.50	5.81	101.03
VIII a. Current tax	24.682	0.16	5.46	47.07
b. Deferred tax charge/credit	13.421	4.35	0.36	53.96
IX Profit/ (Loss) for the period (VII-VIII)	68.770	33.567	16.54	328.17
X Other Comprehensive Income				
Items that will not be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	68.77	33.57	16.54	328.17
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38
Other Equity	68.77	1,802.25	1,490.62	1,474.082
XII Earnings per share (of Rs. 10 each)				
XIII a. Basic (in Rs)	0.79	0.38	0.19	3.75
b. Diluted (in Rs)	0.79	0.38	0.19	3.75

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th August, 2021.
- The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
Note: The figures for the quarter ended March 31, 2021 are balancing figures between the Audited figures of the full financial year ended 31, March 2020 & the published year to date figures upto 9 months ended Dec 31, 2019.
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: August 13, 2021




By Order of the Board
For Concord Drugs Limited
S. N. S. Reddy
Managing Director
DIN: 01764665



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2021, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N.G Rao and Associates
Chartered Accountants
FRN: 009399S**



**G Nageswara Rao
(Partner)
MNo: 207300
UDIN No: 21207300AAABJU9536**

**Place: Hyderabad
Date: 13-08-2021**